Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash from Operations: 2022-2025

Historic Cash from Operations for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -$2.5 million.

  • bioAffinity Technologies' Cash from Operations fell 45.11% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 17.25%. This contributed to the annual value of -$7.3 million for FY2024, which is 20.32% down from last year.
  • As of Q3 2025, bioAffinity Technologies' Cash from Operations stood at -$2.5 million, which was up 6.31% from -$2.6 million recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Cash from Operations peaked at -$376,141 during Q2 2022, and registered a low of -$2.6 million during Q2 2025.
  • Over the past 3 years, bioAffinity Technologies' median Cash from Operations value was -$1.6 million (recorded in 2025), while the average stood at -$1.8 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 261.55% in 2023, then skyrocketed by 30.02% in 2025.
  • bioAffinity Technologies' Cash from Operations (Quarterly) stood at -$1.3 million in 2022, then declined by 24.27% to -$1.6 million in 2023, then dropped by 3.77% to -$1.7 million in 2024, then crashed by 45.11% to -$2.5 million in 2025.
  • Its Cash from Operations stands at -$2.5 million for Q3 2025, versus -$2.6 million for Q2 2025 and -$1.6 million for Q1 2025.